Wysenski Nancy
SEC-identified person · CIK 1294596 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Cytokinetics INC CYTK | Director | filed 2020–2026 |
| Alkermes plc. ALKS | Director | filed 2013–2023 |
| Provention Bio, Inc. PRVB] | Director | filed 2020–2023 |
| Dova Pharmaceuticals, Inc. DOVA | Director | filed 2018–2019 |
| Tetraphase Pharmaceuticals INC TTPH | Director | filed 2014–2019 |
| Inovio Pharmaceuticals, INC. ino | Director | filed 2015–2016 |
| Vertex Pharmaceuticals INC / MA VRTX | EVP, Chief Commercial Officer | filed 2009–2012 |
| Indevus Pharmaceuticals INC IDEV | Director | filed 2009–2009 |
| Endo Pharmaceuticals Holdings INC ENDP | Chief Operating Officer | filed 2007–2009 |
| North American Scientific INC NASM | Director | filed 2006–2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.